Salix Pharmaceuticals LTD (SLXP) Financial Statements (2026 and earlier)

Company Profile

Business Address 8510 COLONNADE CENTER DRIVE
RALEIGH, NC 27615
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments422,578435,260385,1011,157,850817,725817,982
Cash and cash equivalent422,578435,260385,1011,157,850817,725817,982
Receivables507,428481,488437,559133,581389,750282,767
Inventory, net of allowances, customer advances and progress billings151,091142,843145,775104,209106,284105,014
Inventory151,091142,843145,775104,209106,284105,014
Other undisclosed current assets404,419357,622344,945887,029112,918109,377
Total current assets:1,485,5161,417,2131,313,3802,282,6691,426,6771,315,140
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization34,38234,13330,81527,31226,43226,968
Long-term investments and receivables   15,000  
Long-term investments   15,000  
Intangible asset, including goodwill, after accumulated amortization3,198,6633,255,2033,309,975578,419589,296599,803
Goodwill1,348,2641,349,6201,350,376180,909180,907180,903
Intangible asset, excluding goodwill, after accumulated amortization1,850,3991,905,5831,959,599397,510408,389418,900
Restricted cash and investments    750,000  
Other noncurrent assets98,18890,00194,94737,55133,69033,562
Other undisclosed noncurrent assets   (765,000)  
Total noncurrent assets:3,331,2333,379,3373,435,737643,282649,418660,333
TOTAL ASSETS:4,816,7494,796,5504,749,1172,925,9512,076,0951,975,473
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities273,747249,836214,656164,361127,735102,131
Taxes payable    34,820  
Accounts payable49,92638,34443,31832,63227,38620,059
Accrued liabilities223,821211,492171,33896,909100,34982,072
Debt911,279327,45941474949
Other undisclosed current liabilities413,637364,008367,734252,829204,040175,284
Total current liabilities:1,598,663941,303582,431417,237331,824277,464
Noncurrent Liabilities
Long-term debt and lease obligation  1,147,830891,6381,632,050872,642875,696
Long-term debt, excluding current maturities  1,147,830891,6381,632,050872,642875,696
Liabilities, other than long-term debt557,391553,943563,84852,11174,61186,740
Deferred tax liabilities, net542,350543,837550,77242,44665,04765,047
Other liabilities15,04110,10613,0769,6659,56421,693
Other undisclosed noncurrent liabilities 2,019,2701,423,993    
Total noncurrent liabilities:2,576,6613,125,7661,455,4861,684,161947,253962,436
Total liabilities:4,175,3244,067,0692,037,9172,101,3981,279,0771,239,900
Equity
Equity, attributable to parent517,714729,481708,426728,643678,482619,418
Common stock646363636361
Additional paid in capital585,764702,634681,800667,428657,916647,365
Accumulated other comprehensive income (loss)(278)1,5121,7091,7211,111(69)
Retained earnings (accumulated deficit)(67,836)25,27224,85459,43119,392(27,939)
Total equity:517,714729,481708,426728,643678,482619,418
Other undisclosed liabilities and equity123,711 2,002,77495,910118,536116,155
TOTAL LIABILITIES AND EQUITY:4,816,7494,796,5504,749,1172,925,9512,076,0951,975,473

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
Revenues341,547375,540402,979(207,312)238,184235,441
Cost of revenue(162,660)(114,716)(120,981)218,595(45,299)(48,589)
Cost of product and service sold(86,111)(104,567)(116,940) (42,899)(46,489)
Gross profit:178,887260,824281,99811,283192,885186,852
Operating expenses(268,302)(217,848)(302,215)293,981(116,571)(136,710)
Other undisclosed operating income    16,313  
Operating income (loss):(89,415)42,976(20,217)321,57776,31450,142
Nonoperating expense
(Other Nonoperating expense)		(1,737)(23)    
Interest and debt expense(42,998)(42,442)(42,710)66,499(15,497)(15,459)
Other undisclosed income from continuing operations before equity method investments, income taxes   3093,454712622
Income (loss) from continuing operations before income taxes:(134,150)511(62,618)391,53061,52935,305
Income tax expense (benefit)41,042(93)28,041(131,530)(14,198)(14,305)
Income (loss) from continuing operations:(93,108)418(34,577)260,00047,33121,000
Income (loss) before gain (loss) on sale of properties:(93,108)418(34,577)260,00047,33121,000
Net income (loss) available to common stockholders, diluted:(93,108)418(34,577)260,00047,33121,000

Comprehensive Income ($ in thousands)
Annual | Quarterly

12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
Net income (loss):(93,108)418(34,577)260,00047,33121,000
Comprehensive income (loss):(93,108)418(34,577)260,00047,33121,000
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,790)(197)(11)3,2631,180411
Comprehensive income (loss), net of tax, attributable to parent:(94,898)221(34,588)263,26348,51121,411

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: